Royal Bank Of Canada Cyteir Therapeutics, Inc. Transaction History

Royal Bank Of Canada

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$2.84 - $3.13 $15,213 - $16,767	5,357 New	5,357 $16,000
Q2 2023 Aug 14, 2023	BUY	$1.74 - $2.6 $1,539 - $2,301	885 Added 29500.0%	888 $2,000
Q4 2022 Feb 14, 2023	BUY	$1.18 - $1.76 $3 - $5	3 New	3 $0
Q2 2022 Aug 15, 2022	SELL	$1.62 - $4.4 $1,858 - $5,046	-1,147 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$3.39 - $10.51 $3,573 - $11,077	-1,054 Reduced 47.89%	1,147 $4,000
Q4 2021 Feb 14, 2022	BUY	$9.83 - $19.21 $10,046 - $19,632	1,022 Added 86.68%	2,201 $25,000
Q3 2021 Nov 15, 2021	BUY	$14.57 - $21.86 $12,879 - $19,324	884 Added 299.66%	1,179 $20,000
Q2 2021 Aug 16, 2021	BUY	$16.8 - $21.4 $4,956 - $6,313	295 New	295 $6,000

2.47M

Ticker CYT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,413,400
Market Cap $107M
Description
Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for c...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.